Oscar Moradei

Accomplished project leader with 25+ years of success in drug discovery across pharmaceutical and biotechnology sectors. Recognized for managing high-impact medicinal chemistry teams and programs from early-stage discovery through preclinical and early clinical development. Strategic, results-driven, and known for operating with urgency and scientific rigor.

________________________________________

CORE COMPETENCIES

• End-to-end medicinal chemistry expertise: from HTS hit triage to GLP-tox-enabling candidates
• SAR-driven optimization using tools such as Spotfire and StarDrop
• Cross-functional project coordination, including CRO oversight and multidisciplinary integration
• Structure-based drug design, molecular modeling (MOE), and complex organic synthesis

HotSpot Therapeutics Inc., Boston, MA

Senior Director (2017–2025)

Led drug discovery programs focused on immune-mediated diseases through targeting allosteric regulatory sites.

Epizyme Inc., Cambridge, MA

Principal Scientist (2011–2017)

Medicinal chemistry lead for histone methyltransferase inhibitor programs in oncology.

Merck-Frosst., Montreal, QC

Senior Research Scientist (2008–2010)

Research in antivirals (HIV) and metabolic disorders (diabetes).

MethylGene Inc., Montreal, QC

Team Leader (2000–2008)

Led oncology programs focused on HDAC, sirtuin, and kinase inhibitors.

The Ohio State University, Columbus, OH

Postdoctoral Fellow (1997–1999)

Advisor: Prof. Leo A. Paquette

• Completed the first total synthesis of Sclerophytin A and corrected its misassigned structure
• Designed and executed stereocontrolled synthetic strategies to overcome reactivity challenges

Ph.D., Chemistry (Organic Synthesis)

University of Buenos Aires, Argentina

Dissertation: Synthetic Precursors of Thromboxane A2 and Structurally Related Analogs

M.Sc., Chemical Sciences (Organic Chemistry)

University of Buenos Aires, Argentina